Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
OK
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
Mkt Cap
$85.0M
Volume
368.54K
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
OK
OKUR
OK
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
News
·
OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference
Mkt Cap
$85.0M
Volume
368.54K
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Insider
Filings
OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference
OnKure Therapeutics announced that senior management will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 14-16, 2026, in New York. The company will host one-on-one investor meetings during the event. OnKure is advancing IND-enabling activities for next-generation PI3Kα inhibitor candidates OKI-345 and OKI-355, with IND submissions planned for the first half of 2027.
GlobeNewswire Inc. · Aug 31, 2026
OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026
OnKure Therapeutics announced a virtual key opinion leader event on July 15, 2026, featuring prominent researchers to discuss the company's PI3Kα inhibitor drug candidates. The company is advancing two next-generation PI3Kα pan-mutant inhibitor programs (OKI-345 for breast cancer and OKI-355 for vascular anomalies) with plans to submit IND applications to the FDA in the first half of 2027.
GlobeNewswire Inc. · Jul 2, 2026
OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219
OnKure Therapeutics announced positive preliminary data from its first-in-human trial of OKI-219, a PI3Kα inhibitor, showing good tolerability and favorable pharmacokinetics. The company plans to initiate a combination trial with fulvestrant in the second half of 2025.
GlobeNewswire Inc. · Dec 10, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
OK
OKUR
OnKure Therapeutics, Inc. Class A Common Stock
Buy
Sell
Market
Limit
Soon
OKUR
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any OKUR yet.
Related Tickers
Earnings